页 1 从 101 结果
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common form of both senile and presenile dementia in the world and is recognized clinically as relentlessly progressive dementia that presents with increasing loss of memory, intellectual function and disturbances in speech (Merritt,
FIELD OF THE INVENTION
This invention relates to peptidyl compounds useful for a variety of physiological end-use applications. More specifically, di- and tripeptide analogs that are useful in the treatment of neurodegenerative disease states and in the treatment of the degeneration of the neuronal
FIELD OF THE INVENTION
This invention relates to peptidyl compounds useful for a variety of physiological end-use applications. More specifically, peptide and amino acid analogs that are protease inhibitors are provided. These inhibitors are useful in the treatment of certain diseases, including
This application is a PCT application, PCT/CN02/00870, which was filed on Dec. 5, 2002, and claims the priority date of Dec. 6, 2001 in P. R. China.
FIELD OF THE INVENTION
This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds, their preparation methods, compositions
REFERENCE TO CO-PENDING APPLICATIONS
Priority is claimed as a 371 of international of PCT/IL2009/000300, filed on Mar. 16, 2009, which claims priority to Israeli patent application number 190184 filed on Mar. 16, 2008.
FIELD OF THE INVENTION
The invention relates to compositions and methods in the
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
BACKGROUND OF THE INVENTION
1. Field of the Invention
This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
2. Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway
BACKGROUND OF THE INVENTION
Field of the Invention
This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
FIELD OF THE INVENTION
This invention relates to heterocyclic aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,